Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis

Access through your institution Buy or subscribe Neurodevelopmental data among infants treated for ROP are limited. In the hierarchy of evidence, a meta-analysis may potentially provide

higher quality evidence than a single study, and we commend Kaushal et al. for undertaking this important step. A major limitation of pooled data, however, is that results depend upon the

quality and size of included studies. In a meta-analysis, assessing the risk of bias is paramount. The authors used the Modified Newcastle–Ottawa Scale, which, although a convenient

assessment of non-randomized studies for risk of bias, does not remove bias. Inclusion of bias in a meta-analysis does not resolve uncertainty but propagates the bias. This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only

$21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki

E, et al. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS ONE. 2020;15:e0230678. Article 

CAS  Google Scholar  * Blair MP, Shapiro MJ, Ad Hoc Group Concerning Neurodevelopment and antiVEGF. Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded

in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844). Ophthalmology. 2017;124:e74–e75. Article  Google Scholar  * Rodriguez SH, Blair MP, Shapiro MJ, Berrocal AM,

Murray TG, Martinez-Castellanos MA, et al. Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment. Pediatrics. 2020;145:e20200056A. Article  Google

Scholar  * Raghuram K, Isaac M, Yang J, AlAli A, Mireskandari K, Ly LG, et al. Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser. J Perinatol.

2019;39:1300–8. Article  CAS  Google Scholar  * Fan YY, Huang YS, Huang CY, Hsu JF, Shih CP, Hwang YS, et al. Neurodevelopmental outcomes after intravitreal bevacizumab therapy for

retinopathy of prematurity: a prospective case-control study. Ophthalmology. 2019;126:1567–77. Article  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * The

University of Chicago, Chicago, IL, USA Sarah Hilkert Rodriguez * Retina Consultants, Ltd., The University of Chicago, Chicago, IL, USA Michael P. Blair * Retina Consultants, Ltd., The

University of Illinois, Chicago, IL, USA Michael J. Shapiro * Bascom Palmer Eye Institute, Miami, FL, USA Audina M. Berrocal * Calgary Retina Consultants, The University of Calgary, Calgary,

AB, Canada Anna L. Ells * Emory Eye Center, Atlanta, GA, USA G. Baker Hubbard III * Asociacion Para Evitar la Ceguera en Mexico, I.A.P. Hospital “Dr. Luis Sanchez Bulnes”, Cabo San Lucas,

Mexico Maria Ann Martinez-Castellanos * Murray Ocular Oncology and Retina, Miami, FL, USA Timothy G. Murray * Chang Gung Memorial Hospital, Taoyuan, Taiwan Wei-Chi Wu Authors * Sarah Hilkert

Rodriguez View author publications You can also search for this author inPubMed Google Scholar * Michael P. Blair View author publications You can also search for this author inPubMed 

Google Scholar * Michael J. Shapiro View author publications You can also search for this author inPubMed Google Scholar * Audina M. Berrocal View author publications You can also search for

this author inPubMed Google Scholar * Anna L. Ells View author publications You can also search for this author inPubMed Google Scholar * G. Baker Hubbard III View author publications You

can also search for this author inPubMed Google Scholar * Maria Ann Martinez-Castellanos View author publications You can also search for this author inPubMed Google Scholar * Timothy G.

Murray View author publications You can also search for this author inPubMed Google Scholar * Wei-Chi Wu View author publications You can also search for this author inPubMed Google Scholar

CORRESPONDING AUTHOR Correspondence to Sarah Hilkert Rodriguez. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE

THIS ARTICLE Rodriguez, S.H., Blair, M.P., Shapiro, M.J. _et al._ Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and

meta-analysis. _J Perinatol_ 41, 2377–2378 (2021). https://doi.org/10.1038/s41372-021-01133-3 Download citation * Received: 19 April 2021 * Revised: 24 May 2021 * Accepted: 04 June 2021 *

Published: 30 June 2021 * Issue Date: September 2021 * DOI: https://doi.org/10.1038/s41372-021-01133-3 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative